Plasticity in Parkinson's disease: From compensatory usefulness to negative abnormal behaviors

Focus on Parkinson's Disease

Volumn 18, Issue 1, 2006, Pages 5-9

  Linazasoro, Gurutz ^a  

^a Centro de Investigación de Parkinson Policlínica Guipúzcoa   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ABNORMAL BEHAVIOR; AGING; ARTICLE; BASAL GANGLION; BRAIN DEPTH STIMULATION; DENERVATION; DISEASE ASSOCIATION; DYSKINESIA; GENE EXPRESSION PROFILING; GENETIC REGULATION; HUMAN; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MOTOR CORTEX; NERVE CELL PLASTICITY; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; PAIN; PALLIDOTOMY; PARKINSON DISEASE; QUALITY OF LIFE; SENSORIMOTOR NEUROPATHY; TRANSCUTANEOUS NERVE STIMULATION; UNIFIED PARKINSON DISEASE RATING SCALE;

EID: 51749091763     PISSN: 09242015     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci. 1986;9:357-381.
2. Wichmann T, DeLong MR. Functional and pathophystological models of the basal ganglia. Curr Opin Neurobiol. 1996;6:751-758.
3. Parent A, Hazrati LN. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Brain Res Rev. 1995;20:91-127.
4. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991;114:2283-2301.
5. Quartarone A, Siebner HR, Rothwell JC. Task-specific hand dystonia: can too much plasticity be bad for you? Trends Neurosci. 2006;29:192-199.
6. Cooke SF, Bliss TV. Plasticity in the human central nervous system. Brain. 2006;129:1659-1673.
7. Bear MF, Malenka RC. Synaptic plasticity: LTP and LTD. Curr Opin Neurobiol. 1994;4:389-399.
8. Kandel ER. The molecular biology of memory storage: a dialogue between genes and synapses. Science. 2001;294:1030-1038.
9. Pisani A, Centonze D, Bernardi G, et al. Striatal synaptic plasticity: implications for motor learning and Parkinson's disease. Mov Disord. 2005;20:395-402.
10. Malenka RC, Bear MF. LTP and LTD: an embarrassment of riches. Neuron. 2004;44:5-21
11. Linazasoro G. New ideas on the pathophysiology of L-dopa-induced dyskinesias: age, genes and neural plasticity. Trends Pharmacol Sci. 2005;26:391-397.
12. Calabresi P, Giacomini P, Centonze D, et al. Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? Ann Neurol. 2000;47(Suppl 1): S60-68.
13. Cenci MA. Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. Amino Acids. 2002;23:105-109.
14. Calabresi P, Pisani A, Mercuri NB, et al. The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia. Trends Neurosci. 1996;19:19-24.
15. Kuhar MJ, Joyce A, Domínguez G. Genes in drug abuse. Drug Alcohol Depend. 2001;62:157-162.
16. Andersson M, Westin JE, Cenci MA. Time course of striatal DeltaFosB-like immunoreactivity and prodynorphin mRNA levels after discontinuation of chronic dopaminomimetic treatment. Eur J Neurosci. 2003; 17:661-666.
17. Berardelli A, Rothwell JC, Thompson PD, et al. Pathophysiology of bradykinesia in Parkinson's disease. Brain. 2001;124:2131-2146.
18. Cunnington R, Iansek R, Bradshaw JL. Movement-related potentials in Parkinson's disease: external cues and attentional strategies. Mov Disord. 1999;14:63-68.
19. Dick JP, Rothwell JC, Day BL, et al. The Bereitschaftspotential is abnormal in Parkinson's disease. Brain. 1989;112:233-244.
20. Hallett M. Transcranial magnetic stimulation and the human brain. Nature. 2000;406:147-150.
21. Stefan K, Kunesch E, Cohen LG, et al. Induction of plasticity in the human motor cortex by paired associative stimulation. Brain. 2000;123:572-584.
22. Stefan K, Kunesch E, Benecke R, et al. Mechanisms of enhancement of human motor cortex excitability induced by interventional paired associative stimulation. J Physiol. 2002;543:699-708.
23. Wolters A, Sandbrink F, Schlottmann A, et al. A temporally asymmetric Hebbian role governing plasticity in the human motor cortex. J Neurophysiol. 2003;89:2339-2345.
24. Wolters A, Schmidt A, Schramm A, et al. Timing-dependent plasticity in human primary somatosensory cortex. J Physiol. 2005;565:1039-1052.
25. Mir P, Matsunaga K, Gilio F, et al. Dopaminergic drugs restore facilitatory premotor-motor interactions in Parkinson disease. Neurology. 2005;64:1906-1912.
26. Morgance F, Espay AJ, Gunraj C, et al. Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. Brain. 2006;129:1059-1069.
27. Ueki Y, Mima T, Korb MA, et al. Altered plasticity of the human motor cortex in Parkinson's disease. Ann Neural. 2006; 59:60-71.
28. Floel A, Breitenstein C, Hummel F, et al. Dopaminergic influences on formation of a motor memory. Ann Neural. 2005;58:121-130.
29. Gaspar P, Duyckaerts C, Alvarez C, et al. Alterations of dopaminergic and nor-adrenergic innervations in motor cortex in Parkinson's disease. Ann Neurol. 1991;30:365-374.
30. Otani S, Daniel H, Roisin MP, et al. Dopaminergic modulation of long-term synaptic plasticity in rat prefrontal neurons. Cereb Cortex. 2003;13:1251-1256.
31. Mattay VS, Tessitore A, Callicott JH, et al. Dopaminergic modulation of cortical function in patients with Parkinson's disease. Ann Neural. 2002;51:156-164.
32. Rowe J, Stephan KE, Friston K, et al. Attention to action in Parkinson's disease: impaired effective connectivity among frontal cortical regions. Brain. 2002;125:276-289.
33. Rizzo V, Siebner HR, Modugno N, et al. Shaping the excitability of human motor cortex with premotor rTMS. J Physiol. 2004;554:483-495.
34. Calabresi P, Maj R, Pisani A, et al. Long-term synaptic depression in the striatum: physiological and pharmacological characterization. J Neurosci. 1992;12:4224-4233.
35. Chase TN, Oh JD. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann Neurol. 2000;47(Suppl 1):S122-129.
36. Calon F, Hadj Tahar A, Blancher PJ, et al. Dopamine receptor stimulation: biobehavioral and biochemical consequences. Trends Neurosci. 2000;23(Suppl): S92-100.
37. Strafella AP, Paus T, Fraraccio M, et al. Striatal dopamine release induced by repetitive transcranial magnetic stimulation of the human motor cortex. Brain. 2003:126:2609-2615.
38. Goldberg JA, Boraud T, Maraton S, et al. Enhanced synchrony among primary motor cortex neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinson's disease. J Neurosci. 2002;22:4639-4653.
39. Picconi B, Centonze D, Hakansson K, et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci. 2003;6:501-506.
40. Quartarone A, Bagnato S, Rizzo V, et al. Abnormal associative plasticity of the human motor cortex in writer's cramp. Brain. 2003;126:2586-2596.
41. Brown P, Marsden CD. What do the basal ganglia do? Lancet. 1998;351:1801-1804.
42. Brown P. Oscillatory nature of human basal ganglia activity: relationship to the pathophysiology of Parkinson's disease. Mov Disord. 2003;18:357-363.
43. Silberstein P, Oliviero A, Di Lazzaro V, et al. Oscillatory pallidal local field potential activity inversely correlates with limb dyskinesias in Parkinson's disease. Exp Neurol. 2005;194:523-529.
44. Alonso-Frech F, Zamarbide I, Alegre M, et al. Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease. Brain. 2006;129:1748-1757.
45. Foffani G, Ardolino G, Meda B, et al. Altered subthalamo-pallidal synchronisation in parkinsonian dyskinesias. J Neurol Neurosurg Psychiatry. 2005;76:426-428.
46. Rascol O, Sabatini U, Brefel C, et al. Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia. Brain. 1998;121:527-533.
47. Samuel M, Ceballos-Baumann AO, Blin J, et al. Evidence for lateral premotor and parietal overactivity in Parkinson's disease during sequential and bimanual movements. A PET study. Brain. 1997;120:963-976.
48. Sabatini U, Boulanouar K, Fabre N, et al. Cortical motor reorganization in akinetic patients with Parkinson's disease: a functional MRI study. Brain. 2000;123:394-403.
49. Haslinger B, Erhard P, Kämpfe N, et al. Event-related functional magnetic resonance in Parkinson's disease before and after levodopa. Brain. 2001;124:558-570.
50. Samuel M, Ceballos-Baumann AO, Turjanski N, et al. Pallidotomy in Parkinson's disease increases supplementary motor area and prefrontal activation during performance of volitional movements: an H2(15)O PET study. Brain. 1997;120:1301-1313.
51. Limousin P, Greene J, Pollak P, et al. Changes in cerebral activity pattern due to subthalamic nucleus or internal pallidum stimulation in Parkinson's disease. Ann Neurol. 1997;42:283-291.
52. Piccini P, Boecker H, Weeks RA, et al. Dyskinesia correlated regional blood flow changes in Parkinson's disease [abstract]. Neurology. 1997;48(Suppl):A327.
53. Van Gerpen JA, Kumar N, BowerJH, et al. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. Arch Neurol. 2006;63:205-209.
54. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16:448-458.
55. Blancher PJ, Allard P, Gregoire L, et al. Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can J Neurol Sci. 1996;23:189-193.
56. Grandas F, Galiano ML, Tabernero C. Risk factors for levodopa-induced dyskinesias in Parkinson's disease. J Neural. 1999;246:1127-1133.
57. Kumar N, Van Gerpen JA, Bower JH, et al. Levodopa-dyskinesia incidence by age of Parkinson's disease onset. Mov Disord. 2005;20:342-344
58. Quinn N, Critchley P, Marsden CD. Young onset Parkinson's disease. Mov Disord. 1987;2:73-91.
59. Schrag A, Ben-Shlomo Y, Brown R, et al. Young-onset Parkinson's disease revisited-clinical features, natural history, and mortality. Mov Disord. 1998;13:885-894.
60. Barnes CA. Long-term potentiation and the ageing brain. Philos Trans R Soc Lond B Biol Sci. 2003;358:765-772.
61. Deschenes MR, Wilson MH. Age-related differences in synaptic plasticity following muscle unloading. J Neurobiol. 2003;57:246-256.
62. Lu T, Pan Y, Kao SY, et al. Gene regulation and DNA damage in the ageing human brain. Nature. 2004;429:883-891.
63. Linazasoro G. Cell therapy for Parkinson's disease: Only young patients allowed? Cell Transplant. In press 2006.
64. de la Fuente-Fernández R, Schulzer M, Mak E, et al. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. Brain. 2004;127:888-899.
65. de la Fuente-Fernández R, Sossi V, Huang Z, et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain. 2004;127:2747-2754.
66. Sossi V, de la Fuente-Fernández R, Schulzer M, et al. Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications. Brain. 2006;129:1050-1058.
67. Linazasoro G, Leenders KL. PET studies and physiopathology of motor fluctuations in Parkinson's disease. Brain. 2004;127:E15.
68. Ji RR, Kohno T, Moore KA, et al. Central sensitization and LTP: do pain and memory share similar mechanisms? Trends Neurosci. 2003;26:696-705.
69. Klein T, Magerl W, Hopf HC, et al. Perceptual correlates of nociceptive long-term potentiation and long-term depression in humans. J Neurosci. 2004;24:964-971.
70. Goetz CG, Tanner CM, Levy M, et al. Pain in Parkinson's disease. Mov Disord. 1986;1:45-49.
71. Chudler EH, Dong WK. The role of the basal ganglia in nociception and pain. Pain. 1995;60:3-38.
72. Tinazzi M, Del Vesco C, Fincati E, et al. Pain and motor complications in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2006;77:822-825.
73. Henry B, Duty S, Fox SH, et al. Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. Exp Neurol. 2003;183:458-468.
74. Evans AH, Lees AJ. Dopamine dysregulation syndrome in Parkinson's disease. Curr Opin Neurol. 2004;17:393-398.
75. Linazasoro G, Van Blercom N, Lasa A. Hipótesis: Enfermedad de Parkinson, síndrome de deficiencia de recompensa y efectos adictivos de levodopa. Neurología. 2004;19:356-378.
76. Evans AH, Pavese N, Lawrence AD, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neural. 2006;59:852-858.